SYRE
Spyre Therapeutics Inc.
85.70$
-1.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 93.2% | 99.0% | 99.0% | 98.1% | 98.6% | 89.6% | 92.7% | 90.0% | 87.5% | 99.9% | 100.0% | 100.0% | |
| 89.3% | 75.8% | 71.2% | 22.9% | 28.9% | 23.1% | 55.7% | 13.8% | 49.0% | 55.3% | 14.7% | 11.0% | |
| 89.3% | 85.5% | 94.7% | 89.7% | 95.9% | 86.5% | 90.5% | 84.7% | 78.3% | 99.2% | 99.1% | 97.3% | |
| – | 4.4% | 1.8% | 5.5% | 0.4% | – | – | 0.7% | 0.5% | – | – | – | |
| 36.1% | 6.6% | 6.1% | 10.2% | 13.3% | 27.8% | 13.5% | 23.6% | 29.3% | 46.2% | 14.9% | 8.0% | |
| 36.1% | 6.5% | 5.9% | 10.0% | 13.2% | 22.1% | 10.2% | 18.3% | 20.6% | 9.4% | 8.9% | 7.5% | |
| – | – | – | – | – | 0.5% | 0.2% | 0.4% | 0.9% | – | – | – | |
| 11.8% | 0.5% | 0.3% | 0.7% | 0.9% | 3.8% | 1.4% | 3.0% | 1.0% | 0.3% | 0.1% | 1.1% | |
| 63.9% | 93.4% | 93.9% | 89.8% | 86.7% | 72.2% | 86.5% | 76.4% | 70.7% | 53.8% | 85.1% | 92.0% | |
| -419.2% | -61.0% | -67.5% | -129.3% | -150.3% | -234.6% | -170.8% | -310.9% | -598.3% | -223.6% | -159.8% | -145.0% | |
| 18.7% | 1.2% | 0.6% | 1.1% | 1.1% | 1.5% | 1.3% | 2.4% | 4.7% | 2.0% | 7.7% | 8.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.